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We evaluated the immunogenicity and protective activity of plasmid DNA vaccines encoding the influenza virus NP gene (pNP) alone or in
combination with the herpes simplex virus type 1 protein 22 gene (pVP22). Optimal immune responses were observed in BALB/c mice
immunized with the combination of pVP22 plus pNP, as assessed by enzyme-linked immunosorbent assay (ELISA), enzyme-linked immunospot
(ELISPOT) and intracellular cytokine staining (ICCS). These mice also showed maximal resistance following challenge with the A/PR/8/34
(H1N1) and A/Udron/72 (H3N2) strains of influenza virus. The susceptibility of immunized mice to virus infection was significantly increased
following depletion of either CD4+ or CD8+ T cells. These results indicate that a plasmid DNA vaccine encoding pVP22 plus NP induces a high
level of cross-protective immunity against influenza virus subtypes.
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spreadingIntroduction
The hemagglutinin (HA) surface protein of the influenza
virus is highly immunogenic and thus widely considered to be
the antigen of choice for an influenza vaccine. However, HA
has a high mutation rate which may reduce its suitability for use
in a vaccine designed to provide broad protection. In contrast,
the influenza virus nucleoprotein (NP) and M genes have low
rates of mutation (Bot et al., 1996; Cox et al., 2002; Donnelly et
al., 1997; Epstein et al., 2002, 2005; Heinen et al., 2002; Okuda
et al., 2001; Pertmer et al., 1996; Ulmer et al., 1994, 1997). As
previously described (Ulmer et al., 1994), DNA vaccines⁎ Corresponding author. Fax: +81 45 787 2851.
E-mail address: kokuda@med.yokohama-cu.ac.jp (K. Okuda).
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doi:10.1016/j.virol.2006.04.015constructed using NP or M genes can induce cross-protective
immunity. However, some reports suggest that the synthesis of
NP occurs primarily in the nucleus, reducing the immunoge-
nicity of such DNAvaccines (Chen et al., 1999; Kodihalli et al.,
2000; Neumann et al., 1997; Robinson et al., 1997; Whittaker et
al., 1996). Enhancing the antigenicity of NP might increase the
clinical utility of this vaccine strategy.
There are several reports indicating that the tegument protein
VP22 of herpes simplex virus 1 (HSV-1) can increase the
immunogenicity of antigens to which it is fused (Elliott and
O'Hare, 1997; Hung et al., 2001). However, the mechanism by
which this improved immunogenicity is achieved is controver-
sial (Perkins et al., 2005). There is some evidence that this
involves changes in how the encoded fusion protein spreads
between cells (Elliott and O'Hare, 1997; Phelan et al., 1998;
Fig. 2. Expression of the NP, VP221–267/NP and VP22/NP genes in mammalian
cells. Cell lysates obtained from HEK293 cells transfected with pNP (1),
pVP221–267/NP (2), and pVP22/NP (3) were subjected to Western blotting
analysis. The lower figure shows the expression of β-actin. The amount of
protein applied in lanes (1), (2) and (3) is 150 μg, 30 μg and 30 μg, respectively.
The gene expression ratios of NP/β-actin of (2) and (3) were 0.55 and 0.76,
respectively.
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increased immunogenicity was achieved in the absence of such
intercellular spread (Falnes et al., 2001; Perkins et al., 2005;
Lundberg and Johansson, 2001). Despite this uncertainty over
mechanism of action, the ability of VP22 to enhance the
immunogenicity of a co-delivered antigen is well documented
(Dilber et al., 1999; Hung et al., 2001, 2002; Kim et al., 2004;
Michel et al., 2002; Wills et al., 2001).
Another strategy for improving the immunogenicity of
DNA vaccines involves the use of intramuscular electropora-
tion technology (imEPT) (Babiuk et al., 2002). Results indicate
that imEPT reduces the amount of plasmid required to induce
an optimal immune response by >20-fold (our unpublished
data).
The purpose of this study was to assess whether the
immunogenicity of an NP-based DNA vaccine could be
augmented by fusion to VP22. Towards that end, BALB/c
mice were immunized by imEPT with plasmids expressing
genes encoding NP antigen alone, the fused combination of
VP22 with NP (VP22/NP), VP221–267/NP or a mixture of NP
and VP22. Results demonstrate that VP22/NP DNA immuni-
zation induced the highest humoral and cellular immune
response and provided strong cross-protection against influenza
virus challenge.
Results
Differential expression of the NP gene
To detect the expression of NP, VP22/NP and VP221–267/NP
(see Fig. 1 and the Materials and methods section for a
description of these recombinant DNA plasmids), each vaccine
was transfected into HEK293 cells using lipofectin and protein
production analyzed by Western blot. As seen in Fig. 2, the
intensity of the VP22/NP band was greater than that observed
following transfection with VP221–267/NP or NP alone. NoFig. 1. Construction of DNA plasmids. pCAG-NP (pNP) contains the influenza
NP gene and pCAG-VP22/NP (pVP22/NP) contains a fusion gene comprised of
the VP22 gene and the NP gene. pCAG-VP221–267/NP (pVP221–267/NP)
contains a fusion gene comprised of the VP221–267 gene and the NP gene. The
TYQRTRALV peptide represents the MHC class I epitope.band was observed in HEK293 cells transfected with empty
vector alone (data not shown).
Expression of NP protein
To monitor the production of NP protein, transfected cells
were stained with a rabbit anti-NPAb followed by FITC-labeled
anti-rabbit Ig. The nuclei of these cells were counterstained with
4,4,6-diamidino-2-phenylindole (DAPI). A high level of NP
protein expression was observed in cells transfected with
pVP22/NP when compared to the NP or pVP221–267/NP
plasmids (Fig. 3).
Humoral response of vaccinated mice
BALB/c mice were immunized with each plasmid construct,
and serum anti-NP levels evaluated by ELISA. Mice immu-
nized with pVP22/NP had the highest anti-NP titer of all
vaccinated groups (Fig. 4). In contrast, mice immunized with
pVP221–267/NP (the truncated form of the VP22 protein, Elliott
and O'Hare, 1997) showed no adjuvant activity for antibody
production. Our results are consistent with the report of Elliott
and O'Hare.
IFN-γ response of vaccinated mice
Spleen cells isolated from immunized mice were re-
stimulated in vitro with a peptide encoding an immunodominant
MHC binding fragment of NP (Bodmer et al., 1988). The
number of antigen-specific IFN-γ-producing cells in the
pVP22/NP-immunized group was significantly higher than
that in the pNP group (P < 0.05, Fig. 5). The number of antigen-
specific IFN-γ-producing cells was slightly increased in
recipients of pNP plus pVP22, but not in animals immunized
with pVP221–267/NP.
Fig. 3. Expression of the influenza NP and VP22/NP genes in mammalian cells. HEK293 cells transfected with pNP (top), pVP221–267/NP (middle) or pVP22/NP
(bottom) gene. Transfected cells were stained by DAPI (left column) and FITC (middle column). These merge figures (right column) were observed under the
fluorescence microscope (×300). The FITC-labeled cells containing NP.
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producing CD8+ cells was found to be significantly increased in
the pVP22/NP vs. NP immunized groups (Fig. 6B). This
analysis also confirmed that pVP22/NP induced a significant
increase in the number of IFN-γ-producing CD8+ cells when
compared to pVP22 plus pNP (P < 0.05). pVP22 plus pNP
elicited a modest increase in the number of IFN-γ-producing
CD8+ cells which did not differ significantly from animals
immunized with pNP alone.
Body weight and survival rate following viral challenge
Two weeks after the final immunization, vaccinated mice
were challenged intranasally (i.n.) with 5LD50 of the A/PR/8/34Fig. 4. Production of IgG against influenza protein in vaccinated mice. In each g
pVP221 67/NP, pVP22/NP or pVP22 + pNP (mixture) by imEPT. Two weeks aft
influenza NP protein was determined by ELISA. Data represent the mean ± SE(H1N1) strain of flu. All of the control mice died from infection
within 8 days of challenge, whereas all of the mice vaccinated
with pVP22/NP survived for the 2-week duration of the
experiment (Fig. 7A). 33% of mice vaccinated with pNP alone
survived, but none of the pVp221–267/NP-vaccinated animals.
Similarly, control mice continually lost weight following
challenge, whereas the pVP22/NP-immunized group recovered
from their acute weight loss by day 10. In the pNP-immunized
group, the few mice that survived also showed weight
recovery. By comparison, only a slight increase in weight
was observed in among surviving pVP221–267/NP-immunized
animals (Fig. 7B).
Independent cohorts of vaccinated mice were challenged
with the A/Udron/72(H3N2) strain of influenza virus. 80% ofroup, 8–10 mice were immunized twice either with the empty vector, pNP,
er the last immunization, sera were collected. The total IgG titer against the
of each group.
Fig. 5. Frequency of influenza protein-primed IFN-γ-secreting cells in vaccinated mice. In each group, 8–10 mice were immunized twice either with the empty vector,
pNP, pVP221–267/NP, pVP22/NP, pVP22 + pNP (mixture) or pVP22 by imEPT. The splenocytes of these mice were used for an IFN-γ ELISPOTassay 1 week after the
last immunization. The results are given as IFN-γ SFC/106 cells, and the data represent the mean ± SE of each group.
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of mice immunized with pNP alone and none of the recipients
of the pVP221–267/NP plasmid (Fig. 8A). Changes in body
weight consistent with the survival findings were also
observed (Fig. 8B). Based on these results, it appears that
pVP22/NP vaccination induces significant cross-protective
immunity.
Duration of protective immunity
To determine whether vaccination elicited long-lasting
protective immunity, mice were challenged with A/PR/8/34
6 months after the final immunization. As shown in Table 1,
protective immunity persisted even at this late time point in
pVP22/NP-vaccinated mice. In contrast, relatively little protec-
tive immunity was observed in the pNP immunized group.
Mechanism of protection against A/PR/8/34 challenge
The effect of depleting CD4+ or CD8+ cells from pVP22/
NP-immunized mice on their survival following viral challenge
was examined. Vaccinated mice were injected with monoclonal
antibodies (mAbs) against CD4 or CD8, based on reports that
this completely depleted the relevant cell populations (Dialynas
et al., 1983; Epstein et al., 1997, 2000; Sarmiento et al., 1980).
Depletion of CD4+ cells at the time of pVP22/NP immunization
greatly reduced protection against subsequent influenza chal-
lenge (Table 2). In contrast, early depletion of CD8+ cells had a
smaller effect on survival.
These T cell populations were then depleted immediately
prior to A/PR/8/34 challenge. Under these conditions, the
depletion of the CD8+ cells greatly reduced protection. Taken
together, these findings suggest that CD4+ T cells play an
important role during the inductive phase of anti-flu immunity
in pVP22/NP plasmid vaccinated mice, whereas CD8+ T cells
are important during the effector phase of protection.Discussion
Current results clearly demonstrate that a plasmid DNA
vaccine encoding the NP protein of influenza fused to the
pVP22 protein of HSV-1 induced higher levels of protective
immunity against challenge with influenza A/PR/8/34 or A/
Udorn/72 than pNP alone. Moreover, this protective immunity
persisted for at least 6 months after final vaccination.
The induction of cross-protection by pNP was reported by
Ulmer et al. (1994). However, the magnitude of this protection
was modest, and its durability uncertain. It is reported that the
NP tends to remain localized to the nucleus, which might
explain its relatively weak immunogenicity (Anton et al., 1999;
Biswas et al., 1998; Bullido et al., 2000; Neumann et al., 1997;
O'Neill et al., 1998). To overcome this drawback, we fused NP
to VP22 (pVP22/NP) and used as a control the truncated form of
VP22 (VP1–267) that does not enhance immunity (Elliott and
O'Hare, 1997). The mechanism by which VP22 enhances
immunity is controversial. VP22 is a major tegument protein
reported to promote intercellular transport; that is, the protein
spreads from the cell in which it is expressed to a large number
of surrounding cells (Brewis et al., 2003; Elliott and O'Hare,
1997; Phelan et al., 1998; Stroh et al., 2003; Zender et al.,
2002a, 2002b). More recently, this mechanism was challenged
and reported to be an artifact of methanol fixation (Lundberg
and Johansson, 2001). Whatever the mechanism, VP22 is
believed to enhance the ability of transfected antigen to prime
antigen-presenting cells (APCs) and to induce cross-protection
when released from non-professional APCs (Michel et al.,
2002).
In the current study, the expression of NP was enhanced by
fusion to VP22. Immunofluorescence studies suggest that this
expression was generally limited to the cytoplasm of
transfected cells (Fig. 3). In contrast, truncated VP1–267 failed
to enhance the expression of NP (Figs. 2 and 3) and thus did
not boost induction of anti-flu immunity. To further improve
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Fig. 7. Survival rate (A) and body weight changes (B) of vaccinated mice after challenge with influenza A/PR/8/34. The empty-vector-vaccinated mice (cross),
pVP22/NP-vaccinated mice (closed diamond), pNP-vaccinated mice (open square) and pVP221–267/NP-vaccinated mice (closed triangle) were challenged
intranasally (i.n.) with 5LD50 of influenza A/PR/8/34 2 weeks after the last vaccination. The survival rate and body weight changes were monitored for the
subsequent 14 days. Each group consisted of 8–12 mice. The data of two other separate experiments showed similar results.
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administered it by electroporation. There is considerable
evidence that electroporation improves the cellular uptake
and immunogenicity of DNA plasmids in vivo (Widera et al.,
2000).
Results indicate that the pVP22/NP vaccine induced a
stronger NP-specific Ab and IFN-γ response and elicited
stronger and more durable protection against subsequent
influenza challenge than the pNP vaccine alone (Figs. 4–8).
In contrast, there was no statistically significant effect of co-
administering pNP with pVP22 (Figs. 5 and 6). These findings
support the conclusion that simultaneous expression of VP22
and NP in the same cell is critical to increase the immunoge-
nicity of NP.
To clarify the mechanism by which pVP22/NP vaccination
induces protection against influenza virus infection, CD4 and
CD8 T cell populations were depleted at the time of
immunization or at the time of challenge. Results showed that
CD4+ depletion at the time of DNAvaccination greatly reducedFig. 6. ICCS assay. Frequency of influenza protein-primed IFN-γ-producing CD8+ Tc
empty vector, pNP, pVP22/NP, pVP221–267/NP or pVP22 + pNP (mixture) by imEPT
the last immunization. The typical percentages of IFN-γ-producing cells in CD8+ T c
CD8+ T cells of mice immunized with each plasmid. A statistically significant diffeprotective immunity against A/PR/8/34 challenge. Thus, CD4+
T cells appear to play an important role during the inductive
phase of immunity. In contrast, CD8+ T cells played an
important role in protecting mice during challenge. These
findings are consistent with those of Kim et al. (Kim et al.,
2004; Ulmer et al., 1998), who showed that depletion of CD8+
T cells caused complete abrogation of protection. In contrast,
Epstein et al. (2000) reported that DNA vaccination induced
protection from influenza challenge that was independent of
CD4+ or CD8+ T cells. In that study, protection was abrogated
by in vivo depletion of CD90. While we cannot account for the
unexpected findings of Epstein et al., they may reflect
differences in the method of immunization (i.m. vs. imEPT)
or strain of the challenge virus, but most likely reflected their
inclusion of M in addition to NP in their plasmid DNAvaccine,
whereas we studied VP22 fused to NP. While further studies
into the mechanism of CD90-dependent immunity may clarify
these inconsistencies, the current results clearly demonstrated
that CD4+ cells are important during the induction phase whileells in vaccinated mice. In each group, 6–8 mice were immunized either with the
. The splenocytes of these mice were used for an IFN-γ ICCS assay 1 week after
ells are shown in panel A. Panel B represents the mean ± SE of IFN-γ-producing
rence (P < 0.05) was observed among these groups.
Fig. 8. Survival rate (A) and body weight changes (B) of vaccinated mice after challenge with influenza A/Udron/72. The empty-vector-vaccinated mice (cross),
pVP22/NP-vaccinated mice (closed diamond), pNP-vaccinated mice (open square) and pVP221–267/NP-vaccinated mice (closed triangle) were challenged i.n. with 5
LD50 of influenza A/Udron/72 2 weeks after the last vaccination. The mortality rate and body weight changes were monitored for the subsequent 14 days. Each group
consisted of 8–12 mice. The data of two other separate experiments showed similar results.
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protections following pVP22/NP immunization. The results
support continued efforts towards optimizing the immunoge-
nicity of therapeutic DNA vaccines.
Materials and methods
Mice
Male BALB/c mice (6 weeks old) were used for vaccination
and challenge studies. All mice were maintained with free
access to sterile food and water.
Construction of recombinant DNA plasmids
The plasmid encoding the NP gene derived from influenza
A/PR8/34(H1N1) was kindly provided by Dr. S. Tamura,
National Institute of Infectious Diseases, Japan, and the plasmid
encoding the VP22 gene derived from HSV-1 was kindly
provided by Dr. Petter O'Hare, Marie Curie Research Institute,
UK. PCR amplification was carried out using the following
primers: NP sense, 5′ACC GCT CGA GAT GGC GTC TCA
AGG CAC CAA AC3′(containing XhoI site as linker (under-lined)) and antisense, 5′GAC GCG TCG ACT TAATTA TCG
TAT TCC TCT GCA TTG3′ (containing SalI site as linker
(underlined)); VP22 sense, 5′GAA GAT CTA CCATGA CCT
CTC GCC GCT C3′ (containing BglII site as linker (under-
lined)) and antisense, 5′CGG GAT CCC TCG ACG GGC CGT
GGG CGA GA3′ (containing BamHI site as linker (under-
lined)). The VP221–267 genes were prepared as described
previously (Elliott and O'Hare, 1997; Leslie et al., 1996). To
construct the hybrid gene VP22/NP, NP gene fragments were
cut by XhoI and VP22 gene fragments were cut by BamHI; the
recessed 3 ends were filled using the klenow enzyme and were
tandemly ligated. Another hybrid gene VP221–267/NP was
prepared in the same manner. To obtain pCAGGS-NP (pNP),
pCAGGS-VP22 (pVP22), pCAGGS-VP22/NP (pVP22/NP) or
pCAGGS-VP221–267/NP (pVP221–267/NP) constructs, each
gene fragment was introduced into the pCAGGS vector, a
mammalian expression vector.
Western blotting analysis of expressed protein
HEK293 cells were plated at 1 × 105 cells per well into 6-well
plates (Corning). The cells were transfected with 1 μg of pDNA
by using the transfection reagent PolyFect (Qiagen) according to
Table 1
Contribution of CD4+ and CD8+ cells in protective immunity by pVP22/NP
against the A/PR/8/34 challenge




A. Induction phase of immunization
1. pVP22/NP + NRIg a 12/13 92.3
2. pVP22/NP + anti-CD8 mAb 10/14 71.4
3. pVP22/NP + anti-CD4 mAb 3/14 21.4
B. Effector phase of immunization
4. pVP22/NP + NRIg a 13/15 86.7
5. pVP22/NP + anti-CD8 mAb 2/14 14.3
6. pVP22/NP + anti-CD4 mAb 11/15 73.3
C. Control
7. empty vector 0/15 0
Mice in group 2 and 3 were injected i.p. with 1 mg each of anti-CD8 or anti-CD4
mAb on days −3 and −1 of the induction phase of immunization. On day 0, all
mice were immunized with 50 μg of pVP22/NP by imEPT. The same
elimination treatment steps were performed after 4 weeks. On day 43, all mice
were challenged i.n. with 5 LD50 of A/PR/8/34. On days 43, 45, 48 and 40, 1 mg
of anti-CD8 or anti-CD4 mAb was injected i.p. into mice in groups 5 and 6 and
was challenged i.n. with 5LD50 of A/PR/8/34 on day 51. The mortality rate was
monitored for 2 weeks.
a NRIg, normal rabbit immunoglobulin. Other experimental data showed
similar results.
Table 2





1. Empty vector # immunized mice 0/15 0
2. Mice immunized with pVP22/NP 13/15 86.7
3. Mice immunized with pNP 2/15 13.3
Six months after the last immunization, each mouse was challenged with 5 LD50
of A/PR/8/34. After 20 days, the percentage of dead mice was calculated. A
significant difference was observed between 1 and 2 (P < 0.05) and between 2
and 3 (P < 0.05). Other experimental data showed similar results.
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separated using 4–20% polyacrylamide gel electrophoresis
(Tris–glycine gel, Invitrogen) by employing Xcell SureLock™
MiniCell apparatus (Invitrogen) according to the manufacturer's
protocol. The protein from the gel was then transferred to
nitrocellulose by electroblotting (Invitrogen). An ECLWestern
blotting kit (Amersham Biosciences) was used with an anti-NP
mAb to detect antigen expression from DNA vaccines.
Immunofluorescence staining of expressed NP gene
HEK293 cells were plated at 1 × 103 cells per well into 12-
well plates (Nunc, Roskilde, Denmark). The cells were
transfected with 5 μg of pNP, pVP221–267/NP or pVP22/NP by
using the transfection reagent PolyFect (Qiagen) according to the
manufacturer's guidelines. After 48 h, the transfected cells were
fixed by ethanol and rinsed in 2ml of 0.15M phosphate-buffered
saline (PBS) containing 1% bovine serum albumin (BSA). After
rinsing with PBS, the cells were reacted by anti-influenza NPAb
(Dr. T. Tanaka, Jichi Med. Sch., Japan) followed by staining with
FITC-labeled anti-rabbit Ig Ab (MBL, Nagoya, Japan). DAPI
(Vector Lab, CA, USA) was used for the staining of the nuclei of
the cells. After staining, the cells were analyzed under
fluorescence microscopy (KEYENCE, Tokyo, Japan).
Immunization by imEPT
For DNA immunization, 6- to 8-week-old BALB/c mice
(SLC, Shizuoka, Japan) were used; 50 μl of plasmid solution
(1 mg/ml in saline) containing either pNP, pVP22/NP, pVP221–
267/NP, pVP22 or a mixture of pNP and pVP22 (pNP + pVP22)
was injected into the quadriceps muscle. The injection site waselectroporated with a constant field strength (30 V/cm,
50 ms × 3 pulses) by using a CUY21 EDIT electroporator
(Nepa Gene, Tokyo, Japan). A booster immunization was
performed at 4 weeks after the first immunization.
Enzyme-linked immunosorbent assay
Enzyme-linked immunosorbent assay (ELISA) was per-
formed as described elsewhere (Okuda et al., 2001). In brief, 96-
well microtiter plates were coated with 5 μg/ml of influenza NP,
incubated overnight at 4 °C and washed with PBST. They were
then treated with 100 μl of serially diluted antisera. The bound
immunoglobulin was quantified using an affinity-purified
horseradish-peroxidase (HRP)-labeled antimouse Ab (Sigma).
The mean Ab titer was expressed as the reciprocal of the serial
serum dilution.
ELISPOT assay
Two weeks after the final immunization, IFN-γ ELISPOT
assay was performed. In brief, MultiScreen-IP plates (Millipore,
Bedford, MA) were coated with 50 μl of 10 μg/ml purified rat
antimouse IFN-γ antibody (XMG1.2, PharMingen, CA) in PBS
overnight at 4 °C. The plate was then blocked with PBS
containing 5% BSA and 0.025% Tween 20 for 2 h at room
temperature. Lymphocytes (1–10 × 105) that were isolated from
the spleen were added to each well in triplicate. The spleen cells
were stimulated with or without 10 μg/ml of the influenza
peptide (TYQRTRALV) for 24 h at 37 °C. After incubation, the
cells were removed and incubated with 0.5 μg/ml of biotinylated
antimouse IFN-γ antibody (PharMingen) for 2 h at 37 °C
followed by the addition of 100 μl/well of 0.2% alkaline
phosphatase streptavidin (Vector, CA) in PBS containing 0.05%
Tween 20 and 5% BSA for 1.5 h. Finally, the plate was treated
with 50 μl/well of BCIP/NBT membrane phosphatase (Kirke-
gaard and Perry Laboratories, MD) at room temperature for
20 min, and the reaction was terminated by holding the plate
under running distilled water. The number of spots was counted
using a computer-assisted video image analyzer. The results
were expressed as spot-forming cells (SFC) per million cells.
ICCS assay
IFN-γ-secreting CD8+ cells were detected using the protocol
recommended by the manufacturer (Cytofix/CytoPerm Plus Kit,
56 S. Saha et al. / Virology 354 (2006) 48–57PharMingen, San Diego, CA, USA). In brief, lymphocytes
were isolated from the mouse spleen, and a single cell
suspension was incubated with 10 μg/ml of the influenza
peptide (TYQRTRALV) for 24 h at 37 °C. At 2 h before the
end of incubation, 1 μg/ml of GolgiPlug was added. The cells
were washed and blocked with 4% normal mouse sera and
stained with PE-conjugated antimouse CD8 Ab (Ly-2,
PharMingen). The cells were then suspended in 250 μl of
Cytofix/Cytoperm solution at 4 °C for 20 min, washed with
Perm/Wash solution and stained with antimouse IFN-γ Ab
conjugated with FITC (PharMingen) at 4 °C for 30 min
followed by flow cytometric analysis.
Virus challenge
The influenza virus strains used here were A/PR/8/34 and
A/Udron/72 that were obtained from Dr. S. Tamura (National
Institute of Infectious Diseases, Japan). The virus was grown
in 10-day-old embryonated chicken eggs and purified by
sucrose density gradient ultracentrifuge. Two weeks after the
last immunization, the mice were anesthetized with diethyl
ether and infected simultaneously by the intratracheal (i.t.)
route with 5 LD50 of influenza A/PR/8/34 or A/Udron/72 in
30 μl PBS by using a 24-gauge stainless steel animal feeding
needle (Popper and Sons, New York, NY). These mice were
kept under observation from 0 to 14 days, and the body weight
and the survival rates were calculated.
Depletion of CD4+ or CD8+ cells
The mAbs GK1.5 used for in vivo depletion were specific
for mouse CD4 (Dialynas et al., 1983), and mAbs 53.72 is
specific for mouse CD8. All mAbs were rat IgG2b Abs and
had been purified by protein G sepharose. The concentration of
rat IgG2b was measured using radial immunodiffusion by
employing kits from The Binding Site (Birmingham, UK). The
acute depletion protocol has been reported previously (Epstein
et al., 1997). In a preliminary experiment, mice were treated
with mAb and spleen cells were analyzed by flow cytometry to
confirm the depletion.
For the depletion of T cells, mice were injected i.p. with
1 mg anti-CD8 or anti-CD4 mAb on days −3 and −1 of the
induction phase of immunization. On day 0, all mice were
immunized with 50 μg of pVP22/NP by imEPT. The same
depletion treatment steps were performed 4 weeks before the
booster immunization. On day 43, all mice were challenged i.
n. with 5 LD50 of A/PR/8/34. On days 43, 45, 48 and 50, 1 mg
anti-CD8 or anti-CD4 mAb was injected i.p. into mice in
groups 5 and 6, and all mice were challenged on day 51 i.n.
with 5 LD50 of A/PR/8/34. The percent of dead mice was
determined for 2 weeks.
Data analysis
All values were expressed as mean ± SE. Statistical analysis
of the experimental data and controls was performed using the
two-tailed Student's t test or one-way ANOVA.Acknowledgments
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